Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$9.2B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing drugs to treat serious disorders related to the body's stress hormone, cortisol. With a market cap of $9 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in mental health and oncology.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing a slight negative surprise. The stock reacted with a minor decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Corcept's upcoming earnings are mixed, given the lack of analyst estimates and recent performance history. Investors will be looking for signs of recovery or growth after a series of earnings misses.

Bull Case

If Corcept can demonstrate a turnaround in profitability and show positive revenue growth, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to profitability, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's recent history of EPS misses, this figure will be critical in assessing whether Corcept is on a path to profitability.

How is revenue trending for Corcept's key products?

Understanding revenue trends will help investors gauge market demand and the effectiveness of Corcept's sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Corcept to recover from its recent earnings misses, especially if there are signs of improved product demand.

Supporting Evidence

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not align with consensus expectations.

The company's historical performance shows that it can surprise positively, as evidenced by past EPS beats.

Key Risk

If the EPS comes in above $0.10, it could significantly shift market sentiment toward a more bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Corcept can turn around its earnings trajectory and show sustainable revenue growth.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, indicating a strong recovery in profitability.

Bear Confirmed If

An EPS loss greater than $0.40 would confirm the bear case, suggesting ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests a potential stock increase of around 0.61%, confirming a positive sentiment in the market.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.61%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of Corcept's key products and their market reception.
2Management's commentary on strategies to improve profitability moving forward.
3Insights into any new drug developments or pipeline updates.
4Guidance on revenue expectations for the next quarter.
5Responses to analyst questions regarding the company's competitive positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing a slight negative surprise. The stock reacted with a minor decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Corcept can demonstrate a turnaround in profitability and show positive revenue growth, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to profitability, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's recent history of EPS misses, this figure will be critical in assessing whether Corcept is on a path to profitability.

How is revenue trending for Corcept's key products?

Understanding revenue trends will help investors gauge market demand and the effectiveness of Corcept's sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Corcept to recover from its recent earnings misses, especially if there are signs of improved product demand.

Supporting Evidence

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not align with consensus expectations.

The company's historical performance shows that it can surprise positively, as evidenced by past EPS beats.

Key Risk

If the EPS comes in above $0.10, it could significantly shift market sentiment toward a more bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Corcept can turn around its earnings trajectory and show sustainable revenue growth.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, indicating a strong recovery in profitability.

Bear Confirmed If

An EPS loss greater than $0.40 would confirm the bear case, suggesting ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests a potential stock increase of around 0.61%, confirming a positive sentiment in the market.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.61%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of Corcept's key products and their market reception.
2Management's commentary on strategies to improve profitability moving forward.
3Insights into any new drug developments or pipeline updates.
4Guidance on revenue expectations for the next quarter.
5Responses to analyst questions regarding the company's competitive positioning.